Digital diagnostic technologies developer IdentifySensors Biologics has launched a new research facility at the Innovation Centre in Gainesville, Florida, US.

The new facility is aimed at the development of additional products and offers support for product evaluation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is equipped with research and development capabilities to create sensitive graphene biosensors.

IdentifySensors Biologics has engaged a team of scientists specialising in material science, electrochemistry and molecular biology to work at the research centre. It also plans to expand the facility and add more staff members to bolster the research team.

The team is currently accelerating the development of digital biosensors that can identify a wide range of pathogens through the company’s Check4 diagnostics platform.

The Check4diagnostic platform features an assay kit, comprising a sample collection device and test cartridge, as well as a Bluetooth reader, cloud reporting system and mobile application.

Its objective is to enable the simultaneous detection and differentiation of up to three pathogens from a single saliva sample within minutes.

This patented technology uses graphene-based biosensors to selectively detect particular nucleic acid sequences.

In addition, the platform operates at a molecular gene level and does not require enzymatic amplification or reagents.

The company has so far tested biosensors for respiratory pathogens, including Covid-19, Influenza, respiratory syncytial virus and other pathogens.

The facility is expected to soon start assessing products for upcoming regulatory submissions.

Furthermore, it will involve the development of novel sensors that can quickly identify pathogens, including sexually transmitted diseases Lyme, rotavirus, norovirus and adenovirus.

IdentifySensors CEO Greg Hummer stated that the company’s long-term plans comprise biosensors intended to quickly identify non-pathogen diseases.

Hummer further said: “We have an outstanding group of scientists who have taken this technology from the laboratory and made it commercially viable for large-scale production.

“We look forward to submitting this technology to the FDA this year and sharing our data with investors and strategic partners.”